After studying the visual responses of fruit flies with different types of Parkinson's disease, biologists at the University of York believe they may be on to a new biomarker that could be used to detect the early-onset form of the disease.
NeuroDerm has received written confirmation from the FDA that it can file for approval of its Parkinson's disease treatment on the strength of data from one clinical trial, freeing it of the need to run a second, 360-person study. But with the FDA also demanding additional GMP documents from NeuroDerm's device supplier, investors were unsure whether the update was good or bad news.
To treat many neurological diseases, drugs must first pass the blood-brain barrier. But that barrier has formed around the brain to block dangerous substances and, in turn, it thwarts about 98% of drugs, according to a group of Boston scientists. That team has since developed a technique to make crossing the blood-brain barrier less of a hindrance.
A leukemia drug already in use could prove effective in treating Parkinson's disease, according to a tiny, single-arm study involving Novartis' Tasigna (nilotinib).
Researchers at King's College London have unraveled a new gene associated with nerve function, a discovery that could eventually lead to treatment of those with neurodegenerative diseases like Parkinson's.
A group of scientists has concluded that a noninheritable form of Parkinson's disease (PD) may be caused by functional changes in the immune regulating gene interferon-beta (IFNβ). And correction of IFNβ with gene therapy can prevent neuronal death and disease progression in a mouse model of PD.
The NIH funded GreatLakes NeuroTechnologies' deep brain stimulator for Parkinson's disease to the tune of $1.9 million.
St. Jude Medical has received a CE mark for its latest neuromodulation technology--the Infinity Deep Brain Stimulation System to treat movement disorders. It expects to get sign-off from the FDA and to launch the system in the U.S. before year's end. The franchise is the latest addition to St. Jude's neuromodulation business, which last quarter grew faster than the company's other groups in cardiac rhythm management, atrial fibrillation and cardiovascular.
Scientists from the University of North Carolina at Chapel Hill have genetically modified white blood cells (known as macrophages) to make glial cell-derived neurotrophic factor--GDNF. The research was published in PLoS ONE, and the downstream effect of such work could benefit patients with neurodegenerative disorders such as Parkinson's.
Roche is using smartphones to gather data on participants in a Parkinson's disease clinical trial between site visits. The devices will enable both active and passive data collection, with patients being asked to complete daily tests and smartphone sensors gathering information as they go about their lives.